GlobalData highlights expansion and innovation in digital health tech for sleep apnea

Inspire Medical Systems recently secured FDA approval for its Inspire V therapy system, a therapy system for obstructive sleep apnea treatment. This achievement highlights the increasing integration of advanced technology in the management of neurological disorders, fitting into the broader industry shift towards precision medicine, as reflected in the FDA’s recent push for innovative solutions in neurological disease management. The rapid expansion and innovation in digital health technologies, coupled with developments like Inspire’s therapy system, signals a positive shift in patient care for sleep apnea, according to GlobalData.

According to GlobalData, the market for neurological devices was valued at $12.5 billion in 2023 and is expected to grow by a CAGR of 4.60 per cent to reach $20.9 billion by 2033. This growth underscores the increasing importance and demand for advanced diagnostic and monitoring technologies in neurology, including those targeting Parkinson’s disease.

Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, comments: “The market for neurological devices is witnessing significant growth and diversification. The growth of the market is supported primarily by the continuous increase in neurological disorder prevalence due to the ageing population and changing lifestyles.”

GlobalData projects that with the continuous advancements in technology and the introduction of innovative therapies, the landscape of neurological devices is set to transform, offering new hope to millions affected by neurological diseases such as sleep apnea.

Stinchcombe adds, “While developments in digital health technologies are noteworthy, innovations like Inspire V Therapy System are truly transformative in the field of neurology. The FDA approval of the Inspire V therapy system represents a significant advancement in neurological disease management, underscoring the effectiveness of integrating sophisticated systems for precise therapeutic interventions. As the industry continues to focus on both proven and novel solutions, technologies like Inspire V therapy system are pivotal in broadening the horizons of neurology diagnostics and improving patient outcomes.”

GlobalData’s analysis reflects the recent emphasis on wearable technologies and digital health apps—such as those leveraging Apple Watch data to monitor obstructive sleep apnea—indicating a parallel innovation trajectory. While wearable technologies facilitate continuous monitoring outside clinical settings, sophisticated tools like Inspire’s neurostimulator enhance therapeutic interventions, offering a holistic approach to disease management.

Stinchcombe concludes, “In the face of an ageing population and a rising incidence of sleep apnea, the advancements we’re witnessing are encouraging for those affected. The FDA approval of Inspire’s neurostimulator is particularly notable, reflecting a major leap in integrating advanced technologies for more precise and effective management of neurological disorders. Together with the FDA’s initiative to enhance AI-driven diagnostics, these advancements are poised to dramatically improve the landscape of neurology, enhancing both diagnostics and patient outcomes significantly.”

Edits made by EH News Bureau